February 18, 2008 – OrbusNeich’s Genous Bio-engineered R stent is feasible and safe for use in acute myocardial infarction (AMI) patients, according to a paper published in the American Heart Journal (2008; Vol. 155, Issue 1: 128-132).
The paper, based on a study of 120 acute ST-elevation myocardial infarction (STEMI) patients who received a Genous stent, reports there was no incidence of late thrombosis and that the revascularization rate of 2.5 percent at six months is highly acceptable when compared to published primary percutaneous coronary intervention (PCI) rates for bare metal stents. The paper also highlighted that there was a low rate of major adverse cardiac events (MACE): 4.2 percent at 30 days and 5.8 percent at six months.
Entitled "Use of endothelial progenitor cell capture stent (Genous Bio-engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow up," the paper was authored by Huay Cheem Tan, M.D. The study was conducted at National University Hospital and Tan Tock Seng Hospital in Singapore.
Genous is coated with an antibody and is designed to capture a patient’s endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.
For more information: www.OrbusNeich.com
April 17, 2024 
